Please try another search
Marizyme, Inc., a multi-technology biomedical company, develops and commercializes medical technologies to enhances patients health. It’s product portfolio includes DuraGraft, a first-in-class, De Novo granted and CE marked intra-operative vascular graft storage and flushing solution used during coronary artery bypass graft (CABG) surgeries; MATLOC, a point-of-care, lab-on-chip technology platform, developed for quantitative chronic kidney disease assessment; and Krillase, a protein enzyme that acts to break protein bonds and has applications in wound debridement, wound healing, dental care and thrombosi. The company also engages in the development of MAR-FG-001, a fat grafting technology for the use during fat grafting procedures. Marizyme, Inc. was formerly known as GBS Enterprises Incorporated and changed its name to Marizyme, Inc. in March 2018. The company was incorporated in 2007 and is based in Jupiter, Florida.
Name | Age | Since | Title |
---|---|---|---|
Michael R. Stewart | 67 | 2022 | Independent Director |
Terry A. Brostowin | 64 | 2018 | Independent Director |
David L. Barthel | 66 | 2021 | CEO, Secretary & Director |
Nilesh Patel | 59 | 2022 | Independent Director |
Vithalbhai D. Dhaduk | 70 | 2021 | Independent Chairman of the Board |
William G. Hearl | 66 | 2020 | Independent Director |
George Kovalyov | 39 | 2021 | CFO, Treasurer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review